OncoCyte Corp (OCX) Stock Rating Lowered by Zacks Investment Research
OncoCyte Corp (NYSEAMERICAN:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Saturday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, ValuEngine cut shares of OncoCyte Corp from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th.
A hedge fund recently raised its stake in OncoCyte Corp stock. Broadwood Capital Inc. raised its stake in shares of OncoCyte Corp (NYSEAMERICAN:OCX) by 17.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,596,680 shares of the biotechnology company’s stock after acquiring an additional 540,000 shares during the period. OncoCyte Corp makes up 4.5% of Broadwood Capital Inc.’s holdings, making the stock its 5th biggest holding. Broadwood Capital Inc. owned approximately 11.48% of OncoCyte Corp worth $27,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
About OncoCyte Corp
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Stock Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related stocks with our FREE daily email newsletter.